ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 257 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,998,607 | +18.1% | 168,259 | +52.8% | 0.35% | +16.1% |
| Q2 2023 | $5,080,068 | +15.0% | 110,120 | +0.0% | 0.30% | +8.3% |
| Q1 2023 | $4,415,654 | +73.9% | 110,116 | +100.6% | 0.28% | +56.8% |
| Q4 2022 | $2,539,441 | +9.5% | 54,884 | -2.0% | 0.18% | +15.8% |
| Q3 2022 | $2,320,000 | -30.5% | 56,018 | +0.1% | 0.15% | -27.6% |
| Q2 2022 | $3,339,000 | -18.2% | 55,960 | -0.5% | 0.21% | +7.7% |
| Q1 2022 | $4,082,000 | -13.5% | 56,215 | +0.1% | 0.20% | -4.9% |
| Q4 2021 | $4,721,000 | -9.9% | 56,144 | -3.4% | 0.20% | -10.1% |
| Q3 2021 | $5,239,000 | -7.3% | 58,092 | -2.0% | 0.23% | -4.2% |
| Q2 2021 | $5,651,000 | -16.9% | 59,271 | -0.7% | 0.24% | -22.2% |
| Q1 2021 | $6,799,000 | – | 59,712 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |